Basics Taysha Gene Therapies, Inc. IPO Date: September 24, 2020 Sector: Healthcare Industry: Biotech Market Cap: $1.4B Activated in VL: True Average Daily Range Avg Daily Range: $0.28 | 4.18% Avg Daily Range (30 D): $0.17 | 4.22% Avg Daily Range (90 D): $0.10 | 2.88% Institutional Daily Volume Avg Daily Volume: 1.52M Avg Daily Volume (30 D): 7.9M Avg Daily Volume (90 D): 4.39M Trade Size Avg Trade Size (Sh.): 207 Avg Trade Size (Sh.) (30 D): 212 Avg Trade Size (Sh.) (90 D): 206 Institutional Trades Total Inst.Trades: 416 Avg Inst. Trade: $1.9M Avg Inst. Trade (30 D): $1.85M Avg Inst. Trade (90 D): $1.74M Avg Inst. Trade Volume: .61M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.6M Avg Closing Trade (30 D): $2.63M Avg Closing Trade (90 D): $1.77M Avg Closing Volume: 760K     News Oct 17, 2025 @ 1:00 PM Sandhoff Disease Treatment Market Size Projects US... Source: Towards Healthcare Sep 5, 2025 @ 12:00 PM Taysha Gene Therapies Announces Inducement Grant U... Source: Hayleigh Collins Aug 1, 2025 @ 9:06 PM Taysha Gene Therapies Announces Inducement Grant U... Source: Hayleigh Collins Jun 3, 2025 @ 9:17 PM Taysha Gene Therapies Announces Details for Oral P... Source: N/A May 29, 2025 @ 2:40 AM Taysha Gene Therapies Announces Pricing of Public ... Source: N/A Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.34 $-.09 $-.08 Diluted EPS $-.34 $-.09 $-.08 Revenue $ 8.1M $ 1.99M $ 2.3M Gross Profit $ $ $ Net Income / Loss $ -92.72M $ -26.88M $ -21.53M Operating Income / Loss $ -94M $ -26.75M $ -21.42M Cost of Revenue $ $ $ Net Cash Flow $ 140.02M $ 196.17M $ -22.44M PE Ratio